Retinal degeneration

We pioneer new biological approaches to treat retinal degenerative conditions, including age-related macular degeneration and retinitis pigmentosa, which are the most common cause of blindness in the UK.

Retinal degeneration is largely untreatable. We hope to develop new biological approaches to treat these conditions.

We aim to better understand the clinical and biochemical consequences of retinal disease, and explain the genetic and environmental factors contributing to disease pathogenesis.

With a strong translational focus, our goal is to bring these to the clinic and benefit patients with both novel treatments and advancements in existing clinical imaging and diagnostics.

With access to world-leading facilities, Manchester is a leading institution for retinal disease research with key focus areas in:

  • studying the genetics of retinal disorders;
  • immune regulation and its underlying contribution to age-related macular degeneration;
  • ocular angiogenesis and associated diseases such as diabetic retinopathy;
  • clinical imaging, machine vision and the development of novel diagnostic tools;
  • optogenetic approaches to restoring vision in retinal degeneration.